Skip to main content
. 2021 Jun 8;64(12):8486–8509. doi: 10.1021/acs.jmedchem.1c00420

Figure 8.

Figure 8

KT-531 (14) shows promising efficacy and safety in T-PLL primary patient samples. (a) Drug sensitivity scores (DSS)62 of selected HDACi in T-PLL primary patient samples. (b) Box plot of T-PLL synergy scores of KT-531 (14) with bendamustine, idasanutlin, and venetoclax in T-PLL patient samples. (c) Box plot of combination potency cropped to TC50 (toxic concentration in 50% of PBMC population) of KT-531 (14) and venetoclax in T-PLL patient samples and healthy PBMC controls.